Skip to content

Comparing the effect of nettle extract with COCs on the improvement of clinical and paraclinical symptoms of polycystic ovary syndrome.

Comparative efficacy of Nettle (Urtica Dioica) with Combined Oral Contraceptive pills (COCs), on Clinical and Paraclinical Symptoms of Polycystic Ovary Syndrome (PCOS): A Triple Blind Randomized Controlled Trial

Status
Recruiting
Phases
Phase 3
Study type
Interventional
Source
IRCT
Registry ID
IRCT20110606006709N25
Enrollment
60
Registered
2023-05-18
Start date
2023-05-22
Completion date
Unknown
Last updated
2023-05-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Clinical and paraclinical symptoms of polycystic ovary syndrome. Polycystic ovarian syndrome

Interventions

Intervention 1: Nettle extract capsules (containing flavonoids, tannins and sterols) in the number of 30 capsules, one daily for three cycles, which will be prepared and packaged by Sina Navandish Com

Sponsors

Tabriz University of Medical Sciences
Lead Sponsor

Eligibility

Sex/Gender
Female
Age
18 Years to 40 Years

Inclusion criteria

Inclusion criteria: Confirming the diagnosis of PCOS according to the Rotterdam criteria (clinical or biochemical hyperandrogenism, menstrual cycle disorders or polycystic ovary ultrasound signs) Age 18 to 40 years Being literate in reading and writing BMI between 18.5 and 30 Not using hormonal contraceptives or any other type of hormonal medication currently and during the last three months Not wanting to get pregnant

Exclusion criteria

Exclusion criteria: Relative and absolute contraindications of LD tablets (having blood pressure above 14/9, smoking and alcohol use, pregnancy or breastfeeding, alcohol and smoking use, suspicion of breast cancer, coronary heart disease, endometrial carcinoma, etc.) Women undergoing infertility treatment at the time of study. Previous surgery on one or both ovaries. Allergy to nettle Disorders that cause hyperandrogenism (having Cushing's syndrome, adrenal hyperplasia, androgen-producing tumors, etc.)

Design outcomes

Primary

MeasureTime frame
Serum levels of DHEA and total testosterone. Timepoint: Before the start of the intervention and 3 months after the intervention. Method of measurement: By ELISA method in the central laboratory.;Average score of hirsutism. Timepoint: Before the intervention and 3 months after the intervention. Method of measurement: Ferriman–Gallwey scale.

Secondary

MeasureTime frame
Normalization of menstrual cycles. Timepoint: Before the intervention, one month, two months, and three months after the intervention. Method of measurement: Questionnaire made by the researcher and Higham's chart.;Serum level of fasting blood sugar. Timepoint: Before the start of the intervention and and 3 months after the intervention. Method of measurement: By spectrophotometric method in the central laboratory.;Serum levels of gonadotropins (FSH and LH). Timepoint: Before the start of the intervention and and 3 months after the intervention. Method of measurement: By ELISA method in the central laboratory.

Countries

Iran (Islamic Republic of)

Contacts

Public ContactFaride Majdi

Tabriz University of Medical Sciences

faridemajdi211@gmail.com+98 41 3523 0741

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026